Tyr1337
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.2
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Tyr1337  -  VEGFR3 (mouse)

Site Information
KVFyNNEyGEVSQPC   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 2874406

In vivo Characterization
Methods used to characterize site in vivo:
2D analysis ( 1 ) , immunoprecipitation ( 1 ) , mutation of modification site ( 1 , 2 ) , phospho-antibody ( 2 ) , phosphoamino acid analysis ( 1 ) , phosphopeptide mapping ( 1 ) , western blotting ( 1 , 2 )
Relevant cell line - cell type - tissue:
293 (epithelial) ( 1 ) , 3T3 (fibroblast) ( 2 ) , endothelial ( 1 ) , PAE (endothelial) ( 1 ) , Rat2 (fibroblast) ( 2 )

Upstream Regulation
Treatments:
M-CSF ( 2 ) , VEGF ( 1 )

Downstream Regulation
Effects of modification on biological processes:
cell growth, altered ( 2 )

References 

1

Dixelius J, et al. (2003) Ligand-induced vascular endothelial growth factor receptor-3 (VEGFR-3) heterodimerization with VEGFR-2 in primary lymphatic endothelial cells regulates tyrosine phosphorylation sites. J Biol Chem 278, 40973-9
12881528   Curated Info

2

Fournier E, Dubreuil P, Birnbaum D, Borg JP (1995) Mutation at tyrosine residue 1337 abrogates ligand-dependent transforming capacity of the FLT4 receptor. Oncogene 11, 921-31
7675451   Curated Info